Roshni Bhat
Medford, MA| Grant Category: | Fulbright-Nehru Student Research Program |
| Project Title: | Looking Ahead: Visual Outcomes for Pediatric Retinoblastoma Patients |
| Field of Study: | Ophthalmology |
| Home Institution: | Tufts University, Medford, MA |
| Host Institution: | Tata Memorial Hospital, Mumbai, Maharashtra |
| Grant Start Month: | September 2025 |
| Duration of Grant: | Nine months |
Brief Bio:
Roshni Bhat received her BS in biopsychology from Tufts University in May 2023. After graduation, she transitioned from her role as an ophthalmic technician to clinical research assistant at Massachusetts Eye and Ear where she joined the Harvard Ophthalmology Metabolomics in Retina (HOMeR) lab, investigating biomarkers for age-related macular degeneration. In this role, she has successfully presented twice at the annual Association of Research in Vision and Ophthalmology conference and most recently at a New England Ophthalmology Society meeting. Prior to her work at Massachusetts Eye and Ear, Roshni had worked closely with ophthalmologists across the globe to help organize the first Global Refractive Surgery Summit which addressed systemic and specific barriers to accessing refractive surgery, a procedure that can help reduce preventable blindness stemming from uncorrected refractive error. Roshni has also assisted with education research and program design at Tufts University School of Medicine’s Center for Science Education.
Beyond her professional endeavors, Roshni is a lifelong learner who loves to teach as well. She is a classically trained Bharatanatyam dancer, plays tennis and soccer, and is also a trained violinist and vocalist. She is an avid reader and baker who loves to explore.
Roshni’s Fulbright-Nehru research is evaluating the functional vision outcomes for pediatric retinoblastoma patients in order to provide valuable insight into the current standard of care and the efficacy of new treatments. Based in Mumbai, she is working closely with the physicians at Tata Memorial Hospital to assess whether new technologies that salvage parts of the eye are providing significant functional vision outcomes in retinoblastoma patients.